ARTICLE | Emerging Company Profile
NodThera: Inhibiting the inflammasome for NASH
How NodThera is tackling NASH with NLRP3 inflammasome inhibitors
February 16, 2019 12:49 AM UTC
NodThera Ltd. is tackling both the inflammation and fibrosis that drive NASH by inhibiting the NLRP3 inflammasome, a target few companies have interrogated for the indication.
With a £28 million ($37 million) series A led by Sofinnova Partners and 5AM Ventures, NodThera plans to take its lead compound, NT-0167, through early Phase II testing...
BCIQ Company Profiles
BCIQ Target Profiles
NLR family pyrin domain containing 3 (NLRP3) (NALP3) (CIAS1)